BlossomHill Therapeutics closed $100 million in a Series B financing led by Colt Ventures to advance its pipeline of in-house discovery and development programs for multiple high-need cancers and autoimmune diseases.
BlossomHill Therapeutics closed $100 million in a Series B financing led by Colt Ventures to advance its pipeline of in-house discovery and development programs for multiple high-need cancers and autoimmune diseases.
02/29/24, 1:15 PM
Location
san diegoMoney raised
$100 million
Industry
biotechnology
healthcare
Round Type
series b
Investors
H&D Asset Management, Plaisance Capital Management Llc, Hercules Bio Ventures Partners Llc, Vivo Capital, Orbi Med, Cormorant Asset Management, Colt Ventures
BlossomHill Therapeutics announced the closing of a $100 million Series B financing round led by Colt Ventures, with participation from new and existing investors such as Cormorant Asset Management, OrbiMed, Vivo Capital, Hercules BioVentures Partners LLC, Plaisance Capital Management LLC and H&D Asset Management, among others. The company plans to use the proceeds to advance its pipeline of multiple in-house discovery and development programs for multiple high-need cancers and autoimmune diseases into the clinic.
Company Info
Location
san diego, california, united states
Additional Info
BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. The company is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D., and biotech business veteran, Y. Peter Li, Ph.D., M.B.A. BlossomHill Therapeutics, Inc. is headquartered in San Diego, California.